Jeremiah A Alt1, Richard R Orlandi1, Jess C Mace2, Zachary M Soler3, Timothy L Smith2. 1. Sinus and Skull Base Surgery Program, Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Utah, Salt Lake City, Utah. 2. Division of Rhinology and Sinus/Skull Base Surgery, Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland. 3. Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, South Carolina, U.S.A.
Abstract
OBJECTIVES: There is little consensus regarding the prognostic value of symptom duration in predicting clinical disease severity or quality-of-life (QOL) outcomes in patients with chronic rhinosinusitis (CRS). Our objectives were to: 1) determine if patients with longer symptom duration have worse preoperative disease severity and/or QOL, and 2) determine if delayed surgical intervention influences outcomes of endoscopic sinus surgery (ESS). METHODS: Patients diagnosed with CRS were prospectively enrolled into a multicenter cohort study and observed 14.7 (standard deviaton {SD} ± 4.8) months on average following primary ESS. Preoperative symptom duration was stratified into short-term (< 12 months), middle-term (12-60 months), and long-term (> 60 months). Disease severity was assessed using endoscopy and computed tomography. Disease-specific QOL was measured with the 22-item Sinonasal Outcome Test (SNOT-22) and Rhinosinusitis Disability Index. Adjusted bivariate and multivariate associations between symptom duration, disease severity, and QOL scores were evaluated. RESULTS: One hundred and thirteen patients met inclusion criteria with 35 patients lost to postoperative follow-up. No significant differences in preoperative disease severity or QOL scores were reported between symptom duration subgroups. Participants in the long-term symptom subgroup reported significantly greater mean postoperative improvement on SNOT-22 total scores (n = 28; -36.3[± 22.2]) compared to both short-term (n = 27; -23.4[SD ± 11.3]; P = 0.039) and middle-term (n = 23; -23.5[SD ± 20.1]; P = 0.050) subgroups. Postoperative QOL improvements in the long-term symptom subgroup remained significantly greater (P ≤ 0.036) after multivariate adjustment. CONCLUSIONS: Symptom duration was not associated with mean preoperative disease severity or QOL. Patients with long-term symptom duration reported the greatest mean postoperative QOL improvement, suggesting that delayed surgical intervention may not reduce QOL improvements following ESS. LEVEL OF EVIDENCE: 2c Laryngoscope, 129:303-311, 2019.
OBJECTIVES: There is little consensus regarding the prognostic value of symptom duration in predicting clinical disease severity or quality-of-life (QOL) outcomes in patients with chronic rhinosinusitis (CRS). Our objectives were to: 1) determine if patients with longer symptom duration have worse preoperative disease severity and/or QOL, and 2) determine if delayed surgical intervention influences outcomes of endoscopic sinus surgery (ESS). METHODS:Patients diagnosed with CRS were prospectively enrolled into a multicenter cohort study and observed 14.7 (standard deviaton {SD} ± 4.8) months on average following primary ESS. Preoperative symptom duration was stratified into short-term (< 12 months), middle-term (12-60 months), and long-term (> 60 months). Disease severity was assessed using endoscopy and computed tomography. Disease-specific QOL was measured with the 22-item Sinonasal Outcome Test (SNOT-22) and Rhinosinusitis Disability Index. Adjusted bivariate and multivariate associations between symptom duration, disease severity, and QOL scores were evaluated. RESULTS: One hundred and thirteen patients met inclusion criteria with 35 patients lost to postoperative follow-up. No significant differences in preoperative disease severity or QOL scores were reported between symptom duration subgroups. Participants in the long-term symptom subgroup reported significantly greater mean postoperative improvement on SNOT-22 total scores (n = 28; -36.3[± 22.2]) compared to both short-term (n = 27; -23.4[SD ± 11.3]; P = 0.039) and middle-term (n = 23; -23.5[SD ± 20.1]; P = 0.050) subgroups. Postoperative QOL improvements in the long-term symptom subgroup remained significantly greater (P ≤ 0.036) after multivariate adjustment. CONCLUSIONS: Symptom duration was not associated with mean preoperative disease severity or QOL. Patients with long-term symptom duration reported the greatest mean postoperative QOL improvement, suggesting that delayed surgical intervention may not reduce QOL improvements following ESS. LEVEL OF EVIDENCE: 2c Laryngoscope, 129:303-311, 2019.
Authors: Zachary M Soler; Luke Rudmik; Peter H Hwang; Jess C Mace; Rodney J Schlosser; Timothy L Smith Journal: Laryngoscope Date: 2013-07-15 Impact factor: 3.325
Authors: Joshua M Levy; Jess C Mace; Todd E Bodner; Jeremiah A Alt; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2017-05-26 Impact factor: 3.858
Authors: Adam S DeConde; Jess C Mace; Jeremiah A Alt; Luke Rudmik; Zachary M Soler; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2014-12-15 Impact factor: 3.858
Authors: Timothy L Smith; Jamie R Litvack; Peter H Hwang; Todd A Loehrl; Jess C Mace; Karen J Fong; Kenneth E James Journal: Otolaryngol Head Neck Surg Date: 2010-01 Impact factor: 3.497
Authors: Timothy Q Do; Henry P Barham; Peter Earls; Raymond Sacks; Jenna M Christensen; Janet Rimmer; Richard J Harvey Journal: Int Forum Allergy Rhinol Date: 2016-03-17 Impact factor: 3.858
Authors: Kristine A Smith; Richard R Orlandi; Gretchen Oakley; Huong Meeks; Karen Curtin; Jeremiah A Alt Journal: Int Forum Allergy Rhinol Date: 2018-12-20 Impact factor: 3.858
Authors: Daniel M Beswick; Jess C Mace; Zachary M Soler; Luke Rudmik; Jeremiah A Alt; Kristine A Smith; Kara Y Detwiller; Vijay R Ramakrishnan; Timothy L Smith Journal: Int Forum Allergy Rhinol Date: 2019-06-27 Impact factor: 3.858
Authors: Daniel M Beswick; Timothy L Smith; Jess C Mace; Jeremiah A Alt; Nyssa F Farrell; Vijay R Ramakrishnan; Rodney J Schlosser; Zachary M Soler Journal: Int Forum Allergy Rhinol Date: 2020-06-18 Impact factor: 3.858